Effectiveness and Safety of Zingiber Officinale Transdermal Patch for Acne Vulgaris; Study of Interleukin 1 and Skin Microbiome
Launched by HASANUDDIN UNIVERSITY · Jan 16, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment for mild to moderate acne vulgaris, which is a common skin condition that causes pimples. The researchers want to see how effective and safe a 5% Zingiber officinale (ginger) transdermal patch is when used on one side of the face, while the other side receives no patch. Participants will also apply a cream called tretinoin every night to help with their acne. Over the course of 21 days, the researchers will check how many pimples are on each side of the face and take samples to study the skin's bacteria and certain substances related to inflammation.
To be eligible for this trial, participants need to be female, between the ages of 15 and 45, and have mild to moderate acne with at least three visible pimples on their face. Those who have had recent treatments for acne or certain medications, or who are pregnant or breastfeeding, cannot participate. If you join the study, you’ll apply the patch and cream as directed, and you'll be monitored for changes in your skin over three weeks. This trial is currently looking for participants, so it could be a good opportunity for those seeking new treatment options for acne.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • female
- • 15-45 years old
- • mild to moderate acne vulgaris according to Lehmann criteria
- • minimal 3 pustules on face that are distributed on right and left sides
- Exclusion Criteria:
- • history of allergy to ingredients that is used in research
- • history of topical acne medication and steroid in the last 2 weeks
- • history of medical aesthetic procedure such as laser and chemical peeling in the last 2 weeks
- • history of oral antibiotic therapy in the last 6 weeks
- • history of oral isotretinoin therapy in the last 6 months
- • history of probiotic consumption in the last 3 weeks
- • pregnancy and lactation
About Hasanuddin University
Hasanuddin University is a prestigious academic institution based in Indonesia, dedicated to advancing healthcare research and education. As a clinical trial sponsor, the university leverages its extensive expertise in medical and health sciences to conduct innovative research aimed at improving patient outcomes and addressing public health challenges. With a commitment to ethical research practices and collaboration with local and international partners, Hasanuddin University plays a vital role in contributing to the body of knowledge in clinical sciences, fostering advancements in treatment methodologies, and enhancing healthcare delivery in the region.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Makassar, South Sulawesi, Indonesia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported